KEVIN HAMILL
VICE PRESIDENT
JANSSEN BUSINESS DEVELOPMENT
IMMUNOLOGY
Kevin Hamill is Vice President, Business Development for the Immunology Therapeutic Area (TA) at Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all business development activities in support of the Immunology TA, including transactions, acquisitions, scientific licensing and alliance management.
Kevin has a track record of over 23 years of success within the pharmaceutical industry, with launch experience in specialty care, primary care, and orphan products in complex and competitive markets. His commercialization experience includes early design, life cycle planning, and mature brand management as well as business development.
Since joining Janssen, Kevin has made significant contributions across Immunology serving as Vice President, Strategic Account Management for Janssen’s Strategic Customer Group and as Senior Director of Janssen’s Immunology Biosimilars and Portfolio Strategy. Kevin began his career at Janssen as National Sales Director for Gastroenterology, successfully launching STELARA® (ustekinumab) in Crohn’s disease, while continuing to grow REMICADE® (infliximab) in the face of significant biosimilar competition.
Prior to his roles at Janssen, Kevin held positions of increasing responsibility at AstraZeneca. Most recently, he was the Head of Marketing for the U.S. Diabetes Franchise, leading commercial strategy and marketing operations for nine products.
Kevin holds a Bachelor of Science degree in Chemistry from the University of Richmond.
Follow Kevin on LinkedIn here.